ADC Therapeutics SA reports results for the quarter ended in September - Earnings Summary

ADC Therapeutics SA

03/11/2021 11:27

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss of 93 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 92 cents per share.
* Revenue was $13.15 million​;  analysts expected $7.39
million. 
* ADC Therapeutics SA's reported EPS for the quarter was a loss
of 93 cents​.
* The mean earnings estimate of analysts had fallen by
about 3.5% in the last three months.​ 
* In the last 30 days there have been no negative revisions of
earnings estimates 
* ADC Therapeutics SA shares had risen by 7.4% this quarter and
lost 8.8% so far this year.
* The company reported a quarterly loss of $71.55 million.
* Wall Street's median 12-month price target for ADC
Therapeutics SA is $43.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 3 at 11:27 a.m.
 ​All figures in US dollars unless otherwise stated